Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer.

von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B, Fenwick K, Simon R, Marx A, Sauter G, Lise S, Matthews N, Gerlinger M.

Nat Commun. 2020 Jan 16;11(1):139. doi: 10.1038/s41467-019-13915-7.

2.

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.

Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, Rao S, Watkins D, Chau I, Coukos G, Racle J, Gfeller D, Starling N, Cunningham D, Bassani-Sternberg M, Gerlinger M.

J Immunother Cancer. 2019 Nov 18;7(1):309. doi: 10.1186/s40425-019-0769-8.

3.

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M.

Cancer Cell. 2019 Jul 8;36(1):35-50.e9. doi: 10.1016/j.ccell.2019.05.013.

4.

Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.

Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft SY, Rana I, Begum R, Assiotis I, Matthews N, Rao S, Watkins D, Chau I, Cunningham D, Starling N, Gerlinger M.

Cancers (Basel). 2019 May 27;11(5). pii: E736. doi: 10.3390/cancers11050736.

5.

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M.

J Immunother Cancer. 2019 Apr 15;7(1):101. doi: 10.1186/s40425-019-0575-3.

6.

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B, Fenwick K, Herman B, Matthews N, O'Leary B, Hulkki S, Gonzalez De Castro D, Patel A, Wotherspoon A, Okachi A, Rana I, Begum R, Davies MN, Powles T, von Loga K, Hubank M, Turner N, Watkins D, Chau I, Cunningham D, Lise S, Starling N, Gerlinger M.

Clin Chem. 2018 Nov;64(11):1626-1635. doi: 10.1373/clinchem.2018.289629. Epub 2018 Aug 27.

7.

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine.

Lipinski KA, Barber LJ, Davies MN, Ashenden M, Sottoriva A, Gerlinger M.

Trends Cancer. 2016 Jan;2(1):49-63. doi: 10.1016/j.trecan.2015.11.003. Epub 2016 Jan 29. Review.

8.

Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale.

Barber LJ, Davies MN, Gerlinger M.

Curr Opin Genet Dev. 2015 Feb;30:1-6. doi: 10.1016/j.gde.2014.12.001. Epub 2014 Dec 31. Review.

9.

The genomic landscape of oesophagogastric junctional adenocarcinoma.

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A.

J Pathol. 2013 Nov;231(3):301-10.

PMID:
24308032
10.

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB.

Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.

11.

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.

Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. No abstract available.

PMID:
23524863
12.

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A.

J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140.

PMID:
23165508
13.

Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.

Barber LJ, Rosa Rosa JM, Kozarewa I, Fenwick K, Assiotis I, Mitsopoulos C, Sims D, Hakas J, Zvelebil M, Lord CJ, Ashworth A.

PLoS One. 2011;6(7):e21639. doi: 10.1371/journal.pone.0021639. Epub 2011 Jul 5.

14.

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.

Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A.

EMBO Mol Med. 2009 Sep;1(6-7):323-37. doi: 10.1002/emmm.200900040.

15.

The MRT-1 nuclease is required for DNA crosslink repair and telomerase activity in vivo in Caenorhabditis elegans.

Meier B, Barber LJ, Liu Y, Shtessel L, Boulton SJ, Gartner A, Ahmed S.

EMBO J. 2009 Nov 18;28(22):3549-63. doi: 10.1038/emboj.2009.278. Epub 2009 Sep 24.

16.

C. elegans: a model of Fanconi anemia and ICL repair.

Youds JL, Barber LJ, Boulton SJ.

Mutat Res. 2009 Jul 31;668(1-2):103-16. doi: 10.1016/j.mrfmmm.2008.11.007. Epub 2008 Nov 19. Review.

PMID:
19059419
17.

FANCJ is a structure-specific DNA helicase associated with the maintenance of genomic G/C tracts.

London TB, Barber LJ, Mosedale G, Kelly GP, Balasubramanian S, Hickson ID, Boulton SJ, Hiom K.

J Biol Chem. 2008 Dec 26;283(52):36132-9. doi: 10.1074/jbc.M808152200. Epub 2008 Oct 31.

18.

RTEL1 maintains genomic stability by suppressing homologous recombination.

Barber LJ, Youds JL, Ward JD, McIlwraith MJ, O'Neil NJ, Petalcorin MI, Martin JS, Collis SJ, Cantor SB, Auclair M, Tissenbaum H, West SC, Rose AM, Boulton SJ.

Cell. 2008 Oct 17;135(2):261-71. doi: 10.1016/j.cell.2008.08.016.

19.

DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair.

Youds JL, Barber LJ, Ward JD, Collis SJ, O'Neil NJ, Boulton SJ, Rose AM.

Mol Cell Biol. 2008 Mar;28(5):1470-9. Epub 2007 Dec 17.

20.

Human SNM1A suppresses the DNA repair defects of yeast pso2 mutants.

Hazrati A, Ramis-Castelltort M, Sarkar S, Barber LJ, Schofield CJ, Hartley JA, McHugh PJ.

DNA Repair (Amst). 2008 Feb 1;7(2):230-8. Epub 2007 Nov 19.

PMID:
18006388
21.

Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.

Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H, Niimi A, Lehmann A, Zhao GY, Hochegger H, Boulton SJ, Takeda S.

Cancer Res. 2007 Sep 15;67(18):8536-43.

22.

Replication blocking lesions present a unique substrate for homologous recombination.

Ward JD, Barber LJ, Petalcorin MI, Yanowitz J, Boulton SJ.

EMBO J. 2007 Jul 25;26(14):3384-96. Epub 2007 Jul 5.

23.

HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability.

Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ.

Nat Cell Biol. 2007 Apr;9(4):391-401. Epub 2007 Mar 25.

24.

A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination.

Zhao GY, Sonoda E, Barber LJ, Oka H, Murakawa Y, Yamada K, Ikura T, Wang X, Kobayashi M, Yamamoto K, Boulton SJ, Takeda S.

Mol Cell. 2007 Mar 9;25(5):663-75.

25.

BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg?

Barber LJ, Boulton SJ.

DNA Repair (Amst). 2006 Dec 9;5(12):1499-504. Epub 2006 Oct 5.

PMID:
17027345
26.

C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair.

Collis SJ, Barber LJ, Ward JD, Martin JS, Boulton SJ.

DNA Repair (Amst). 2006 Nov 8;5(11):1398-406. Epub 2006 Aug 17.

PMID:
16914393
28.

Schizosaccharomyces pombe checkpoint response to DNA interstrand cross-links.

Lambert S, Mason SJ, Barber LJ, Hartley JA, Pearce JA, Carr AM, McHugh PJ.

Mol Cell Biol. 2003 Jul;23(13):4728-37.

29.

AJCN unplugged: easy to use World Wide Web presentation of Journal content.

Barber LJ, McGlade LT, Milot BA, Scales J.

Am J Clin Nutr. 1997 Apr;65(4):1094-6. No abstract available.

PMID:
9094903

Supplemental Content

Loading ...
Support Center